

Provention Bio to Present at the Stifel Virtual Healthcare Conference

RED BANK, N.J., Nov. 11, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that management will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020, at 8:00 am E.T.

A webcast of the presentation can be accessed by visiting the Events and Webcasts section of the Company's website: <http://investors.proventionbio.com/events>. The webcast will be archived on the Company's website for 90 days following the presentation.

About Provention Bio, Inc.:

Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company has submitted a BLA to the FDA for its lead investigational drug candidate, teplizumab, for the delay or prevention of clinical type 1 diabetes (T1D) in at-risk individuals. The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Visit www.proventionbio.com for more information or follow us on Twitter: @Proventiobio

Internet Posting of Information:

Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contact:

Sam Martin, Argot Partners
sam@argotpartners.com
212-600-1902

Media:

Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808

SOURCE Provention Bio, Inc.

<http://investors.proventionbio.com/2020-11-11-Provention-Bio-to-Present-at-the-Stifel-Virtual-Healthcare-Conference>